Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance

Liver Transplantation

Volumn 8, Issue 6, 2002, Pages 505-513

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PREDNISONE; TACROLIMUS;

ANTIGEN PRESENTING CELL; AUTOIMMUNE HEPATITIS; CELL POPULATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; GRAFT REJECTION; HOMEOSTASIS; HUMAN; LIVER TRANSPLANTATION; LYMPHOCYTE; LYMPHOCYTE CLONE; MOLECULAR MIMICRY; PATHOGENESIS; PRIORITY JOURNAL; RECIPIENT; RECURRENT DISEASE; REVIEW; THYMUS DISEASE; TRANSPLANTATION TOLERANCE;

EID: 0036270285     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2002.33485     Document Type: Article

References (92)

1. Current concepts in the diagnosis, pathogenesis, and treatment of autoimmune hepatitis
2. Autoantibodies in liver disease
3. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis
4. Autoimmune hepatitis
5. Understanding the pathogenesis of autoimmune hepatitis
6. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting
7. Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease
8. Recurrence of autoimmune hepatitis following liver transplantation
9. Recurrence of autoimmune hepatitis in children after liver transplantation
10. Acute lobular hepatitis as the first manifestation of recurrent autoimmune hepatitis after orthotopic liver transplantation
11. Outcome of autoimmune hepatitis after liver transplantation
12. Recurrence of autoimmune hepatitis after liver transplantation
13. Recurrence of autoimmune hepatitis after liver transplantation
14. Long-term follow-up after liver transplantation for autoimmune hepatitis: Evidence of recurrence of primary disease
15. Liver transplantation for autoimmune hepatitis
16. Liver transplantation for autoimmune hepatitis: A long-term pathologic study
17. Recurrent autoimmune hepatitis after orthotopic liver transplantation
18. De-novo autoimmune hepatitis after liver transplantation
19. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults
20. De novo hepatitis with autoimmune antibodies and atypical histology
21. Concurrent de novo autoimmune hepatitis and recurrence of primary biliary cirrhosis post-liver transplantation
22. Autoimmune hepatitis as a late complication of liver transplantation
23. Monitoring "de novo" autoimmune hepatitis (LKM positive) by serum type-IV collagen after liver transplant: A paediatric case
24. Posttransplant immune hepatitis in pediatric liver transplant recipients: Incidence and maintenance therapy with azathioprine
25. Response to steroids in de novo autoimmune hepatitis after transplantation
26. International Autoimmune Hepatitis Group report: Review of criteria for diagnosis of autoimmune hepatitis
27. Immunopathology or organ-specific autoimmunity as a consequence of virus infection
28. Break of T cell ignorance to a viral antigen in the liver induces hepatitis
29. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis
30. Genetic bases of autoimmune hepatitis
31. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB1*1301, a marker for pediatric autoimmune hepatitis
32. Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis
33. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis
34. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis
35. CTLA-4 gene polymorphism and susceptibility to type 1 autoimmune hepatitis
36. Apoptotic and effector pathways in autoimmunity
37. An autosomal locus causing autoimmune disease: Autoimmune polyglandular disease type 1 assigned to chromosome 21
38. Molecular mimicry and immune-mediated diseases
39. Molecular mimicry and autoimmunity
40. Pathogenesis of autoimmune hepatitis
41. Autoimmune regulator AIRE: Evidence for genetic differences between autoimmune hepatitis and hepatitis as part of the autoimmune polyglandular syndrome type 1
42. Structural basis of specificity and degeneracy of T cell recognition: Pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell HLA-DR
43. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis
44. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis
45. Autoimmunity and viruses
46. Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein
47. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase
48. Immunological cross-reactivity to multiple autoantigens in patients with liver kidney microsomal type 1 autoimmune hepatitis
49. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition
50. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis
51. Cytochromes P450 and uridine diphosphate-glucuronosyltransferases: Model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease
52. Formimino-transferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis
53. Argininosuccinate lyase: A new autoantigen in liver disease
54. The asialoglycoprotein receptor as target structure in autoimmune liver diseases
55. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis
56. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNA(Ser)Sec complex recognized by autoantibodies from patients with type 1 autoimmune hepatitis
57. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis
58. Immunology of acute and chronic hepatic allograft rejection
59. Molecular mimicry and autoimmune liver disease: Virtuous intentions, malign consequences
60. Molecular mimicry by herpes simplex virus-type 1: Autoimmune disease after viral infection
61. Autoimmune hepatitis and its variant syndromes
62. Effect of cyclosporin A on human lymphocyte responses in vitro III. CsA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primed lymphocytes to TCGF
63. Thymic immunopathology after cyclosporin: Effect of irradiation and age on medullary involution and recovery
64. Suppression or induction of apoptosis by opposing pathways downstream from calcium-activated calcineurin
65. Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD
66. Cyclosporin A-induced autoimmune disease in mice
67. Graft-versus-host disease in cyclosporin A-treated rats after syngeneic and autologous bone marrow reconstitution
68. Immune mechanisms in cyclosporine-induced syngeneic graft-versus-host disease
69. Cyclosporine-induced autoimmunity: Critical role of autoregulation in the prevention of major histocompatibility class II-dependent autoaggression
70. Cyclosporine-induced syngeneic graft-versus-host disease: Recognition of self MHC class II antigens in vivo
71. Cyclosporine-induced syngeneic graft-versus-host disease: Prevention of autoaggression by treatment with monoclonal antibodies to T lymphocyte cell surface determinants and to MHC class II antigens
72. The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506
73. Cyclosporine in the management of corticosteroid-resistant type 1 autoimmune chronic active hepatitis
74. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis
75. Tacrolimus: A potential new treatment for autoimmune chronic active hepatitis: Results of an open-label preliminary trial
76. Cyclosporine therapy in patients with steroid resistant auto-immune hepatitis
77. Short-term cyclosporine induces a remission of autoimmune hepatitis in children
78. Cyclosporin-A is a promising alternative to corticosteroids in autoimmune hepatitis
79. A gender gap in autoimmunity
80. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: A 16-year prospective study
81. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: A second type of "autoimmune" hepatitis
82. Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy
83. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA DR6 (DRB1*1301) haplotype
84. Pediatric and adult forms of type 1 autoimmune hepatitis in Argentina: Evidence for differential genetic predisposition
85. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2
86. Analysis of HLA haplotypes in autoimmune hepatitis type 1: Identifying the major susceptibility locus
87. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals
88. Autoimmune hepatitis following hepatitis A virus infection
89. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation
90. Acute allograft rejection: Incidence, risk factors, and impact on outcome
91. Banff Schema for Grading Liver Allograft Rejection: An international consensus document
92. Working recommendations for the histopathologic staging and reporting of chronic rejection